drugset / Trial / NCT07548606

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

NCT07548606

Phase 1 Completed 14 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelBasic science

Summary

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called itraconazole.

Timeline

Start
2026-05-11
Primary completion
2026-06-01
Completion
2026-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule Oral
Subject Opevesostat Small molecule Oral
Background Fludrocortisone Other / unclassified Oral
Background Prednisone Other / unclassified Oral

Indications

No indication recorded.